NYSE - Nasdaq Real Time Price USD

Bristol-Myers Squibb Company (BMY)

45.15 +0.30 (+0.66%)
As of 10:21 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
45,534,000.00
45,006,000.00
46,159,000.00
46,385,000.00
42,518,000.00
Cost of Revenue
11,059,000.00
10,693,000.00
10,137,000.00
9,940,000.00
11,773,000.00
Gross Profit
34,475,000.00
34,313,000.00
36,022,000.00
36,445,000.00
30,745,000.00
Operating Expense
27,198,000.00
26,118,000.00
26,918,000.00
27,908,000.00
28,568,000.00
Operating Income
7,277,000.00
8,195,000.00
9,104,000.00
8,537,000.00
2,177,000.00
Net Non Operating Interest Income Expense
-1,303,000.00
-1,166,000.00
-1,232,000.00
-1,334,000.00
-1,420,000.00
Other Income Expense
-11,820,000.00
1,411,000.00
-159,000.00
895,000.00
-7,628,000.00
Pretax Income
-5,846,000.00
8,440,000.00
7,713,000.00
8,098,000.00
-6,871,000.00
Tax Provision
289,000.00
400,000.00
1,368,000.00
1,084,000.00
2,124,000.00
Net Income Common Stockholders
-6,148,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
Diluted NI Available to Com Stockholders
-6,148,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
Basic EPS
-3.09
3.88
2.97
3.25
-3.99
Diluted EPS
-3.10
3.86
2.95
3.12
-3.99
Basic Average Shares
2,050,000.00
2,069,000.00
2,130,000.00
2,153,000.00
2,258,000.00
Diluted Average Shares
2,055,500.00
2,078,000.00
2,146,000.00
2,245,000.00
2,258,000.00
Total Expenses
38,257,000.00
36,811,000.00
37,055,000.00
37,848,000.00
40,341,000.00
Net Income from Continuing & Discontinued Operation
-6,148,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
Normalized Income
1,676,000.00
7,997,363.00
7,439,696.00
7,213,999.51
-2,188,770.00
Interest Expense
1,303,000.00
1,166,000.00
1,232,000.00
1,334,000.00
1,420,000.00
Net Interest Income
-1,303,000.00
-1,166,000.00
-1,232,000.00
-1,334,000.00
-1,420,000.00
EBIT
-4,543,000.00
9,606,000.00
8,945,000.00
9,432,000.00
-5,451,000.00
EBITDA
5,320,000.00
19,366,000.00
19,221,000.00
20,118,000.00
4,929,000.00
Reconciled Cost of Revenue
10,344,000.00
9,980,000.00
9,456,000.00
9,277,000.00
11,081,000.00
Reconciled Depreciation
9,863,000.00
9,760,000.00
10,276,000.00
10,686,000.00
10,380,000.00
Net Income from Continuing Operation Net Minority Interest
-6,148,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
Total Unusual Items Excluding Goodwill
-13,040,000.00
29,000.00
-1,352,000.00
-254,000.00
-9,351,000.00
Total Unusual Items
-13,040,000.00
29,000.00
-1,352,000.00
-254,000.00
-9,351,000.00
Normalized EBITDA
18,360,000.00
19,337,000.00
20,573,000.00
20,372,000.00
14,280,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-5,216,000.00
1,363.00
-239,304.00
-34,000.49
-2,524,770.00
12/31/2020 - 6/1/1972

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PFE Pfizer Inc.
25.79
+1.52%
 
ABBV AbbVie Inc.
159.33
-0.18%
 
MRK Merck & Co., Inc.
131.25
+0.04%
 
GILD Gilead Sciences, Inc.
66.76
+2.04%
 
JNJ Johnson & Johnson
146.76
+0.42%
 
AZN AstraZeneca PLC
76.05
+1.17%
 
BIIB Biogen Inc.
216.65
+3.71%
 
LLY Eli Lilly and Company
740.34
+0.93%
 
AMGN Amgen Inc.
273.73
+1.39%
 
SNY Sanofi
49.44
+0.63%